Superworth

Innoviva EV/EBIT INVA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2015.

Today, Nov 2, 2026
7.4×
10-year median
6.5×
Against its 10-year history
65th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.9× to 21.2×
Peer median
8.9×

Innoviva's EV/EBIT is 7.4× as of Nov 2, 2026.

That is above its ten-year median of 6.5×, higher than on 65% of days in the last ten years.

Over that time it ranged from 1.9× in Feb 2023 to 21.2× in Feb 2017.

The median for 10 large drugmakers of a similar size is 8.9×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far7.4×7.0×9.2×
20257.2×5.9×8.3×
20246.7×5.5×15.5×
202315.1×1.9×15.3×
20222.1×2.0×4.9×
20214.3×3.7×4.8×
20203.9×3.2×6.5×
20196.2×4.9×10.3×
20189.0×8.5×14.3×
201712.5×11.4×21.2×
201619.6×18.3×137×
2015123×109×123×

Against its peers

Companies in Drug Manufacturers - General nearest Innoviva's size, closest first, today.

Where Innoviva ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Innoviva

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.